

# Donna Evon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3072432/publications.pdf>

Version: 2024-02-01

58  
papers

1,007  
citations

394421

19  
h-index

477307

29  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 183-192.	4.4	90
2	A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1777-1786.	0.4	63
3	Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 2949-295.	0.4	57
4	Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study. <i>Journal of Hepatology</i> , 2012, 57, 946-952.	3.7	56
5	High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use Comorbidities. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3251-3258.	2.3	47
6	Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1163-1173.	3.7	42
7	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , 2019, 71, 486-497.	3.7	37
8	Religious Coping, Psychological Distress and Disability Among Patients with End-Stage Pulmonary Disease. <i>Journal of Clinical Psychology in Medical Settings</i> , 2004, 11, 179-193.	1.4	36
9	Adherence During Antiviral Treatment Regimens for Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, e41-e50.	2.2	34
10	Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1469-1474.	2.3	33
11	Depressive symptoms and mortality in lung transplant. <i>Clinical Transplantation</i> , 2010, 24, E201-6.	1.6	25
12	Tobacco and alcohol use in lung transplant candidates and recipients. <i>Clinical Transplantation</i> , 2005, 19, 207-214.	1.6	24
13	Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 361-374.	2.0	24
14	Self-Efficacy and Adherence to Antiviral Treatment for Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 76-83.	2.2	24
15	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , 2020, 71, 1894-1909.	7.3	24
16	Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. <i>Journal of Viral Hepatitis</i> , 2013, 20, 536-549.	2.0	23
17	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. <i>PLoS ONE</i> , 2018, 13, e0196908.	2.5	23
18	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140.	7.3	23

#	ARTICLE	IF	CITATIONS
19	Fatigue in Patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN). <i>Digestive Diseases and Sciences</i> , 2016, 61, 1186-1196.	2.3	21
20	Event-level analyses of sex-risk and injection-risk behaviors among nonmedical prescription opioid users. <i>American Journal of Drug and Alcohol Abuse</i> , 2016, 42, 689-697.	2.1	18
21	Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. <i>Journal of Psychosomatic Research</i> , 2011, 71, 349-356.	2.6	17
22	Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1071-1080.	3.7	16
23	Psychometric properties of the <scp>PROMIS</scp> short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1001-1011.	3.7	16
24	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1011-1020.	2.6	16
25	Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1439-1444.	2.3	14
26	Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx095.	0.9	14
27	Pharmacist attitudes and provision of harm reduction services in North Carolina: an exploratory study. <i>Harm Reduction Journal</i> , 2021, 18, 70.	3.2	14
28	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , 2017, 57, 58-68.	1.8	13
29	What Survivorship Means to Liver Transplant Recipients: Qualitative Groundwork for a Survivorship Conceptual Model. <i>Liver Transplantation</i> , 2021, 27, 1454-1467.	2.4	12
30	What's Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment. <i>Patient</i> , 2017, 10, 335-344.	2.7	11
31	A Novel Patient-Reported Outcome-Based Evaluation (PROBE) of Quality of Life in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 640-647.	0.4	11
32	Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 457-468.	3.7	11
33	Patient Knowledge, Beliefs and Barriers to Hepatitis B Care: Results of a Multicenter, Multiethnic Patient Survey. <i>Digestive Diseases and Sciences</i> , 2021, 66, 434-441.	2.3	11
34	What Liver Transplant Recipients Want in a Smartphone Intervention to Enhance Recovery: Prototype for the LiveRight Transplant App. <i>Liver Transplantation</i> , 2021, 27, 584-589.	2.4	11
35	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , 2021, 41, 692-704.	3.9	11
36	Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective. <i>Liver Transplantation</i> , 2022, 28, 422-436.	2.4	11

#	ARTICLE	IF	CITATIONS
37	Pegylated Interferon Pharmacokinetics and Self-Reported Depressive Symptoms During Antiviral Treatment for Chronic Hepatitis C. <i>Pharmacopsychiatry</i> , 2014, 47, 195-201.	3.3	9
38	A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Hepatology Communications</i> , 2020, 4, 1502-1515.	4.3	8
39	Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens. <i>Journal of Viral Hepatitis</i> , 2012, 19, 316-326.	2.0	7
40	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 73-85.	1.8	7
41	"œ If I Get Cured, My Whole Quality of Life Will Change" Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2022, 67, 100-120.	2.3	7
42	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , 2021, 74, 2952-2964.	7.3	7
43	Factors associated with perceived ease of access to syringes in Appalachian North Carolina. <i>Journal of Rural Health</i> , 2023, 39, 212-222.	2.9	5
44	Incorporating Patient-Reported Outcomes Into Hepatitis C Virus Treatment Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1360-1362.	4.4	4
45	Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C. <i>Pilot and Feasibility Studies</i> , 2018, 4, 92.	1.2	4
46	Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C. <i>Contemporary Clinical Trials Communications</i> , 2017, 6, 85-96.	1.1	3
47	Mitigating the Risk of Infectious Diseases Among Rural Drug Users in Western North Carolina: Results of the Southern Appalachia Test, Link, Care (SALT) Health Care Provider Survey. <i>Journal of Rural Health</i> , 2020, 36, 208-216.	2.9	3
48	Symptoms and functioning improve after chronic hepatitis C cure as assessed by the Memorial Symptom Assessment Scale and PROMIS measures. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1491-1495.	2.0	3
49	Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives. <i>Journal of Viral Hepatitis</i> , 2021, 28, 699-709.	2.0	2
50	Willingness to participate in research among black patients with liver disease: A national cross-sectional study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 982-993.	2.0	2
51	Change in Alcohol Use and Association with Positive and Negative Emotions: Results from an Alcohol Treatment Study with Hepatitis C Patients. <i>Alcoholism Treatment Quarterly</i> , 2021, 39, 430-445.	0.8	1
52	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. <i>GastroHep</i> , 2021, 3, 196-208.	0.6	1
53	Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. <i>Journal of Viral Hepatitis</i> , 2022, 29, 795-806.	2.0	1
54	Editorial: patient-reported outcomes in chronic HCV—a PROMIS-ing approach to an ongoing problem. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1320-1321.	3.7	0

#	ARTICLE	IF	CITATIONS
55	2204. In HCV-Infected Patients, Internalized Stigma, but not Experienced Stigma, Is Correlated with Psychological State and Health-Related Quality of Life: Baseline Data from the PROP UP Study. Open Forum Infectious Diseases, 2018, 5, S650-S650.	0.9	0
56	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS-ACO13 HEPAVIH)". Journal of Hepatology, 2020, 72, 592-593.	3.7	0
57	Substance use disorder treatment providers' knowledge and opinions toward testing and treatment of chronic hepatitis C in rural North Carolina.. Journal of Rural Mental Health, 2022, 46, 162-173.	0.9	0
58	Concordance between Patients and Clinicians for Reporting Symptoms Associated with Treatment for Chronic Hepatitis C during a Pragmatic Clinical Trial. GastroHep, 2022, 2022, 1-9.	0.6	0